PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma (TASE:CFBI), a biotechnology company traded on the Tel Aviv Stock Exchange, reports today that a confirmatory Phase IIb trial is now enrolling patients as part of the ongoing development of CF101. The regulatory process in which the Company was involved during the past few months resulted in approvals for the trial in several countries, including Israel. The trial is conducted under an Investigational New Drug (IND).
